Left ventricular myocardium-to-blood ratio >1.5 on 99mTc-HMDP SPECT/CT accurately detects ATTR-CM University of Helsinki #cvnuc #amyloidosis Read now👉bit.ly/43W8YG9

New in JAHA: ASPIRE + expert collaborators outline how #AI could help detect #CardiacAmyloidosis earlier. Strong science. Real-world urgency. Read more: ahajournals.org/doi/10.1161/JA… #Amyloidosis #RareDisease #JAHA_AHA

Is bone avid tracer cardiac scintigraphy always the preferred approach to screen at risk populations for TTR cardiac amyloidosis? Ahmad Masri Columbia Cardiology Fellows OHSU Knight Cardio #cvnuc Read both sides of the debate👇 bit.ly/4kCgv2f

ICYMI: Cardiac PET & PET/CT have earned 🆕 indications in recently published guidelines from the ACC/AHA, European Society of Cardiology, & the The ISHLT. To help you translate these recommendations into practice, Journal of Nuclear Cardiology published a State-of-the-Art Review article documenting where PET is now

🚨 New Publication! 🚨 Our team at @UFF_oficial, with Mouaz Al-Mallah, M.D MSc , just published a systematic review and meta-analysis in the Journal of Nuclear Cardiology : Comparison of PET-CT and CZT-SPECT on MBF measurement : ✅ Good agreement between CZT and PET ! Amazing job : Davi Yahiro

Many #amyloidosis patients face not only a devastating disease but also delayed or missed diagnoses. With treatments available and more in development, faster diagnosis is critical to improving the lives of patients. Learn more about ARC's impact: arci.org/anniversary

Thrilled to share that our review “What Cardiologists Should Know About Amyloidosis” is now published in the Journal of Clinical Medicine! Highlighting early recognition, diagnostics, and therapies for cardiac amyloidosis. 🔗 doi.org/10.3390/jcm141… #CardioTwitter #Amyloidosis

1/5 Just presented a case on cardiac amyloidosis; common yet often underdiagnosed. We walked through diagnosis, management, and especially Afib care. 🫀 #CardioTwitter

New in #JACC: A cross-trial analysis of 3 cardiac amyloidosis #ATTRCM trials reveals time-dependent effects of modern disease-modifying therapies on mortality. Get the details: jacc.org/doi/10.1016/j.… #ATTRMeeting2025 #ATTR2025 #Amyloidosis Muthu Vaduganathan scottdavidsolomon

Presented at #ATTR: Gillmore and colleagues report 24-month results from a phase 1 study of nexiguran ziclumeran, a CRISPR gene-editing approach to treating hereditary transthyretin amyloidosis with polyneuropathy. Full study results: nej.md/46Qhur7

Nexiguran Ziclumeran (nex-z) Gene Editing in Hereditary ATTR with Polyneuropathy. A single dose of nex-z in patients with ATTRv-PN was associated with rapid, deep, and durable reductions in serum TTR levels #amyloidosis #mmsm NEJM nejm.org/doi/full/10.10…

More incredible #CRISPR data with #Nexz published today in NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE.

ARC’s Annual Community Survey captures real-world experiences of #amyloidosis and helps guide care, support, & research. Patients with amyloidosis and their caregivers, we invite you to take part in this year's survey. 👉 Take the survey here: arci.org/survey2025

Hidden culprit in atrial fibrillation? Biopsy reveals atrial amyloidosis—more common with age and structural heart changes. Read more in #EHJ. doi.org/10.1093/eurhea… #cardiotwitter #AtrialFibrillation #CardiacAmyloidosis #AgingHeart European Society of Cardiology Journals European Society of Cardiology

Amyloidosis therapy Mayte Basurto ISCP / International Society of CV Pharmacotherapy

Great educational opportunity! The Heart Failure Society of America is hosting a webinar titled "Understanding and Managing ATTR Amyloidosis" on October 22. If you or someone you know is interested in learning more about this important topic, please check out the informational

🧬 Not all forms of Amyloidosis are hereditary — but they all change lives. Some types are genetic 🧑‍🧑‍🧒‍🧒 Others appear without warning. 😢But every form deserves recognition, understanding, and proper care. 👩🏻‍⚕️ 🎗️Every voice can make a difference 📣

Watch Michelle Kittleson, MD, PhD (@MKittlesonMD) & Senthil Selvaraj, MD, MS, MA (Senthil Selvaraj, MD, MS, MA) discuss updates on Implementing Targeted Therapies in Transthyretin Cardiac #Amyloidosis from #HFSA2025 – to participate, visit: bit.ly/25ATTR-T x.com/i/broadcasts/1…

Data from ATTRibute-CM on the NTproBNP response in the subgroup of variant ATTR patients. Acoramidis mitigated the rise of NTproBNP as compared to placebo #HFSA2025 #CardioTwitter #MedIQHFSA2025

Not only AL! How many amyloidosis type are there that are recognized by the ISA? ~~➡️➡️ 42 types! -Acquired -Genetic -Iatrogenic